ALXN News and Press, Alexion Pharmaceuticals Inc. From 05/06/20

Many of the companies included in this article are in the mix developing treatments for COVID-19, some already have possible therapies in place. But perhaps the thing they have in common the most is how their price charts are governed largely by investor sentiment. Most of these names sold off...

Image source: The Motley Fool. Alexion Pharmaceuticals Inc   (NASDAQ: ALXN) Q1 2020 Earnings Call May 6, 2020 , 8:00 a.m. ET Operator Continue reading

Alexion Pharmaceuticals, Inc. (ALXN) Q1 2020 Results Earnings Conference Call May 06, 2020, 08:00 AM ET Company Participants Chris Stevo - Head of Investor Relations Ludwig Hantson - Chief Executive Officer Aradhana Sarin - Chief Financial Officer John Orloff - Global Head of R...

The following slide deck was published by Alexion Pharmaceuticals, Inc. in conjunction with their 2020 Q1 earnings Read more ...

Alexion Pharmaceuticals ( ALXN ) Q1 results : More news on: Alexion Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, , Read more ...

Alexion Pharmaceuticals (NASDAQ: ALXN ): Q1 Non-GAAP EPS of $3.22 beats by $0.51 ; GAAP EPS of $2.50 beats by $0.26 . More news on: Alexion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

1Q20 total revenues of $1,444.8 million, a 27 percent increase over 1Q19 1Q20 GAAP diluted EPS of $2.50; non-GAAP diluted EPS of $3.22 Received positive CHMP opinion for ULTOMIRIS ® (ravulizumab) in atypical hemolytic uremic syndrome (aHUS) in the EU Advanced ULTOMIRIS as...

Alexion Pharmaceuticals (NASDAQ: ALXN ) is scheduled to announce Q1 earnings results on Wednesday, May 6th, before market open. The consensus EPS Estimate is $2.71 (+13.4% Y/Y) and the consensus Revenue Estimate is $1.37B (+20.2% Y/Y). Over the last 2 years, ALXN has beaten EPS estima...

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the Bank of America Securities 2020 Healthcare Conference, taking place virtually on Tuesday, May 12th, 2020 at 1:00 p.m. ET. An audio webcast of the presentation will be available live. You can access t...

SOUTH SAN FRANCISCO, Calif. , May 5, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) (the "Company" or " Portola ") today announced that it is cancelling its webcast and conference call to discuss the Company's financial results for the first quarter ended March...